Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Young Wha | - |
dc.contributor.author | Han, Jae-Ho | - |
dc.contributor.author | Jeong, Dongjun | - |
dc.contributor.author | Kim, Chang-Jin | - |
dc.date.accessioned | 2021-08-11T09:43:41Z | - |
dc.date.available | 2021-08-11T09:43:41Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 0344-0338 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4429 | - |
dc.description.abstract | We evaluated the relationship between interferon-induced transmembrane protein 1 (IFITM1) expression, epithelial-mesenchymal transition (EMT) signature and angiogenesis in lung adenocarcinoma. Additionally, we examined prognostic significance of IFITM1 according to pTNM stage to confirm that IFITM1 can serve as a complement to the pTNM stage. A total of 141 lung adenocarcinoma specimens were evaluated retrospectively by immunohistochemical staining for IFITM1, EMT markers (e-cadherin, beta-catenin, and vimentin), and CD31 to measure microvessel density. IFITM1 was expressed in 46.8% of the specimens. IFITM1 expression was significantly correlated with increased microvessel density (P = 0.048). However, IFITM1 expression was not associated with three EMT markers. In a multivariate analysis, IFITM1 was an independent prognostic factor for overall survival in a multivariate analysis (hazard ratio: 2.59, P = 0.01). Online database with data from 720 lung adenocarcinoma patients also revealed a negative prognostic significance of IFITM1 (P < 0.001). Furthermore, high IFITM1 expression was significantly correlated with decreased OS rates in each pTNM stage. IFITM1 is significantly correlated with angiogenesis and it may be used as a useful additional prognostic marker to aid pTNM classification. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma | - |
dc.type | Article | - |
dc.publisher.location | 독일 | - |
dc.identifier.doi | 10.1016/j.prp.2019.152444 | - |
dc.identifier.scopusid | 2-s2.0-85065252299 | - |
dc.identifier.wosid | 000474674200009 | - |
dc.identifier.bibliographicCitation | Pathology Research and Practice, v.215, no.7 | - |
dc.citation.title | Pathology Research and Practice | - |
dc.citation.volume | 215 | - |
dc.citation.number | 7 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | INDUCED TRANSMEMBRANE PROTEIN-1 | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | TNM STAGE GROUPINGS | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | 8TH EDITION | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | AGGREGATION | - |
dc.subject.keywordPlus | REVISION | - |
dc.subject.keywordAuthor | Lung adenocarcinoma | - |
dc.subject.keywordAuthor | Interferon-induced transmembrane protein 1 | - |
dc.subject.keywordAuthor | Microvessel | - |
dc.subject.keywordAuthor | Density | - |
dc.subject.keywordAuthor | Epithelial-mesenchymal transition | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.